Drug Trial Radar · NCT02138084
Drug-drug Interaction (DDI) Rifabutin
Last checked: Nov 19, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
May 14, 2014
Primary completion
Jul 24, 2014
Study completion Jul 24, 2014
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- May 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide dosing recommendations for the coadministration of BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for prescribing information purposes
Conditions
- Infection, Human Immunodeficiency Virus
Interventions
BMS-663068Drug
BMS-663068
RifabutinDrug
Rifabutin
RitonavirDrug
Ritonavir
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) of BMS-626529Time frame: Day 2 to Day 15
- Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-626529Time frame: Day 2 to Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.